Oncolytics Biotech EBIT
The EBIT of Oncolytics Biotech (ONC.TO) as of Oct 17, 2026 is -34.98 M CAD. In the previous year, EBIT was -33.79 M CAD — a change of 3.52% (lower).
Get this data via API
Financial Data API
EBIT
-34.98 MCAD
YoY
3.52%
Last updated:
In 2024, Oncolytics Biotech's EBIT was -34.98 M CAD, a 3.52% increase from the -33.79 M CAD EBIT recorded in the previous year.
The Oncolytics Biotech EBIT history
3 Years
10 Years
25 Years
Max
| YEAR | EBIT | YoY |
|---|---|---|
| est | 0.00CAD | -100.00% |
| est | 137.76 MCAD | +867.55% |
| est | 14.24 MCAD | -128.05% |
| est | -50.76 MCAD | +26.60% |
| est | -40.10 MCAD | -28.43% |
| est | -56.03 MCAD | +31.21% |
| est | -42.70 MCAD | +22.07% |
| -34.98 MCAD | +3.52% | |
| -33.79 MCAD | +25.52% | |
| -26.92 MCAD | +2.63% | |
| -26.23 MCAD | +3.02% | |
| -25.46 MCAD | +24.99% | |
| -20.37 MCAD | +17.95% | |
| -17.27 MCAD | +10.14% | |
| -15.68 MCAD | +3.70% | |
| -15.12 MCAD | +4.28% | |
| -14.50 MCAD | -22.00% | |
| -18.59 MCAD | -21.96% | |
| -23.82 MCAD | -35.08% | |
| -36.69 MCAD | +27.75% | |
| -28.72 MCAD | +44.39% | |
| -19.89 MCAD | +23.85% | |
| -16.06 MCAD | -11.47% | |
| -18.14 MCAD | +5.77% | |
| -17.15 MCAD | +8.41% | |
| -15.82 MCAD | +18.77% | |
| -13.32 MCAD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Oncolytics Biotech Revenue
Oncolytics Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Oncolytics Biotech Margins
Oncolytics Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Oncolytics Biotech Stock analysis
EBIT Details
Analyzing Oncolytics Biotech's EBIT
Oncolytics Biotech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Oncolytics Biotech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Oncolytics Biotech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Oncolytics Biotech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Oncolytics Biotech stock
EBIT of Oncolytics Biotech is -34.98 M CAD in 2024.
EBIT of Oncolytics Biotech changed from -33.79 M CAD to -34.98 M CAD, representing a 3.52% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBIT Oncolytics Biotech since 2006 – with annual values, charts, and detailed analysis.
"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.
Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)
EBIT's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Oncolytics Biotech historically and in real time.
The sales revenue is important for evaluating a stock.
EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.
History
The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.
Usage
The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.
Calculation
EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:
EBIT = Net profit + interest and taxes
Example:
Eulerpool: Your source for quantitative stock data
At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more.
Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market.
Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you.
Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool.
Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000
Application
The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.
Use of EBIT in stock investment
Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.
Advantages of EBIT
EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.
Disadvantages of EBIT
There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.
Conclusion
The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Oncolytics Biotech
All Key Metrics — Oncolytics Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth